Loading...

TRAW TRAWS PHARMA INC US FDA Inspections 8-K Filing

TRWS

TRW

TRAWS PHARMA INC

(TRAW)

2025 8-K

Annual Meeting Update

Earnings Announcement

Executive Stock Options

COVID Study Announcement

Management Changes

Asset Purchase Agreement

New Study Approval

Earnings Release

Product Expansion

Clinical Trials

Pre-Market Approval

Corporate Presentation

Financial Statements

Management Changes

Earnings Announcement

Management Changes

COVID-19 Treatment Data

Positive Study Results

Positive Study Results

Compliance Update

Capital Structure Update

Stockholder Meeting

Nasdaq Compliance

Management Changes

Phase 1 Completion

Securities Offering

Partnership Announcement

Partnership Announcement

Product Launch Plans

Earnings Report

Other Special Situation

Filing with Quantitative Data

Financial Results

Other Special Situation

Financial Update

Financial Update

Other Special Situation

Filing with Quantitative Data

Other Special Situation

Financial Update

Management Changes

Clinical Development Update

Clinical Development Update

External Links:

On August 18, 2025, Traws Pharma, Inc. announced they received approval from the Human Research Ethics Committee to start a Phase 2 study of ratutrelvir, a treatment for newly diagnosed COVID patients. The updated corporate presentation will also be available on their website.

AI Assistant

TRAWS PHARMA INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.